Although most primary cutaneous melanomas are treated with surgical excision alone, current international guidelines vary on the optimal size for the surgical margins, which can range from 1 to 3 cm.
Clinical Trials
Navitoclax Plus Dabrafenib and Trametinib Shows Activity in BRAF-Mutant Melanoma
Combination treatment with dabrafenib, trametinib, and navitoclax has demonstrated activity in patients with BRAFV600-mutant, advanced melanoma, according to research presented at the ASCO Annual Meeting 2023.
Combination of mRNA-4157 With Pembrolizumab Improves Survival in Melanoma
In the phase 2 KEYNOTE-942 trial (NCT03897881), mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) led to a reduced risk of developing distant metastasis or death by approximately 65% vs with pembrolizumab alone as adjuvant therapy in patients with resected melanoma at high risk of recurrence, according to findings presented at the 2023 ASCO Annual Meeting.
Adjuvant Chemotherapy Superior to Toripalimab in Resected Mucosal Melanoma
Chemotherapy is more effective than toripalimab as adjuvant therapy in patients with resected mucosal melanoma, according to research presented at the ASCO Annual Meeting 2023.